StocksF › FRPT

Freshpet, Inc. (FRPT) — Earnings Call X-Ray

Our AI read all 38 of FRPT's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2025 · sign up to see
Previous Call Grade
B+
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
38
2016–2025
Avg Candor
7.4/9
evasion 2.2/9
Guidance RaisedHigh CandorSkeptic ReassuredCritic AmmunitionEarly Product, Fast GrowthMargins ExpandingCapex IncreasingReads Rehearsed

Call-by-call analysis

🔒 Q1 2025 earnings call 2025-05-05 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2025 call grade is ready
The full 37-point AI read of FRPT's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

B+ Q4 2024 earnings call 2025-02-20 move ±16.8%

Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: mixedMargins: expandingPricing: stableCapex: increasing
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
Candor 7/9
Specificity 9/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

A Q3 2024 earnings call 2024-11-04 move ±9.8%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: growingCapex: decreasing 14 analysts · 15 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 8/9
Uncertainty 4/9
Promotion 6/9
Stress 1/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

A Q2 2024 earnings call 2024-08-05 move ±12.5%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: growingCapex: decreasing 12 analysts · 23 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B+ Q1 2024 earnings call 2024-05-06 move ±8.9%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: growingCapex: increasing 10 analysts · 20 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 8/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q4 2023 earnings call 2024-02-26 move ±12.7%

Management held guidance steady against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: acceleratingMargins: expandingPricing: stableCapex: flat 16 analysts · 27 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q3 2023 earnings call 2023-11-06 move ±11.2%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: growingCapex: increasing 11 analysts · 25 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
Candor 7/9
Specificity 9/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

A Q2 2023 earnings call 2023-08-07 move ±11.5%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: acceleratingMargins: expandingPricing: stableHeadcount: growingCapex: increasing 11 analysts · 24 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2023 2023-05-08 B maintainedacceleratingexpanding 7/9 2/9
Q4 2022 2023-02-27 C maintainedacceleratingcontracting 7/9 4/9
Q3 2022 2022-11-01 C+ maintainedacceleratingcontracting 7/9 3/9
Q2 2022 2022-08-13 D loweredstablecontracting 7/9 3/9
Q1 2022 2022-05-02 B maintainedacceleratingcontracting 8/9 2/9
Q4 2021 2022-02-28 B maintainedacceleratingcontracting 8/9 2/9
Q3 2021 2021-11-08 D loweredacceleratingcontracting 8/9 3/9
Q2 2021 2021-08-02 B raisedacceleratingcontracting 8/9 4/9
Q1 2021 2021-05-04 B maintainedacceleratingcontracting 8/9 2/9
Q4 2020 2021-02-22 B+ raisedacceleratingcontracting 8/9 2/9
Q3 2020 2020-11-03 B+ maintainedacceleratingstable 8/9 3/9
Q2 2020 2020-08-04 B+ raisedacceleratingexpanding 8/9 2/9
Q1 2020 2020-05-04 C+ loweredacceleratingexpanding 8/9 2/9
Q4 2019 2020-02-25 B maintainedacceleratingstable 7/9 2/9
Q3 2019 2019-11-04 B+ maintainedacceleratingexpanding 7/9 3/9
Q2 2019 2019-08-05 B+ raisedacceleratingcontracting 8/9 2/9
Q1 2019 2019-05-06 B+ maintainedacceleratingexpanding 7/9 2/9
Q4 2018 2019-02-27 A raisedacceleratingcontracting 8/9 1/9
Q3 2018 2018-11-05 B+ maintainedacceleratingcontracting 8/9 1/9
Q2 2018 2018-08-06 B+ raisedacceleratingexpanding 7/9 2/9
Q1 2018 2018-05-07 B maintainedacceleratingcontracting 7/9 2/9
Q4 2017 2018-03-05 B+ raisedacceleratingcontracting 7/9 2/9
Q3 2017 2017-11-06 B+ maintainedacceleratingexpanding 7/9 2/9
Q2 2017 2017-08-07 B+ raisedacceleratingexpanding 7/9 2/9
Q1 2017 2017-05-06 B+ maintainedacceleratingexpanding 8/9 2/9
Q4 2016 2017-03-09 C+ loweredacceleratingcontracting 8/9 2/9
Q3 2016 2016-11-02 C loweredmixedexpanding 7/9 3/9
Q2 2016 2016-08-07 B maintainedacceleratingcontracting 7/9 1/9
Q1 2016 2016-05-04 B maintainedstablecontracting 7/9 2/9
Q4 2015 2016-03-09 B maintainedstablecontracting 7/9 2/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of FRPT's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

B+ Q2 2018 earnings call 2018-08-06

B+ Q2 2017 earnings call 2017-08-07

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAN · The Aaron's Company, IncAAWW · Atlas Air Worldwide HoldABAX · ABAXISABCB · Ameris BancorpABM · ABM Industries IncorporaACBI · Atlantic Capital Bancsha

FRPH   All “F” companies    FRRPF

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.